Let's talk medical research

Antidote’s podcast, Talk of the Towne, hosted by Antidote’s Senior Clinical Informatics Manager, Dr. Richard Towne, is an interview series featuring members of Antidote's partner network. During each episode, Rich and his guests take a closer look at particular therapeutic areas, the latest research developments, and specific pain points that impact the patient population.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that results in weakened breathing and reduced lung function. In the U.S., it is estimated that 50,000 individuals are diagnosed with IPF each year, and 140,000 are estimated to live with the disease in America.

We are excited to announce that we have received the Silver Award from EcoVadis for the second year in a row. EcoVadis is the world’s largest, most trusted provider of business sustainability ratings, with a global network of more than 90,000 companies. Antidote was evaluated within this network to receive this award, and scored in the top 25% of companies focusing on Corporate and Social ...

In the third quarter of 2018, we conducted a survey with SCORR Marketing to learn more about the patient perception of clinical trial participation. This extensive survey involved nearly 4,000 patients from our patient advocacy group partners and provided valuable insights into the demographics of these individuals, their motivations for engaging in research, and what matters most to them ...

Alzheimer’s disease, the most prevalent type of dementia, is diagnosed in more than 6 million Americans. Estimates project that by 2050, 13 million individuals will be diagnosed with Alzheimer’s disease. This condition ranks among the top 10 causes of death in the United States, profoundly impacting those diagnosed, their loved ones, and their caregivers. Currently, Alzheimer’s remains a disease ...

Globally, there are thousands of research studies and clinical trials conducted each year, all with the shared goal of bringing new treatment options and medical devices to the market. However, approximately 80% of clinical trials are delayed or closed because of problems with recruitment.

Are you attending the 13th annual DPharm conference in Boston on September 20-23?

Today, Antidote is excited to announce our collaboration with Beyond Type 1 and JDRF to release the first-ever Spanish-language clinical trial search engine for type 1 diabetes (T1D). This groundbreaking version of Antidote Match™ empowers users to search for type 1 diabetes trials in their preferred language, marking a significant step to improve diversity, equity, and inclusion in diabetes ...

As part of our efforts to better understand patients and their motivations to participate in clinical trials, Antidote and SCORR Marketing partnered on a survey to gain a deeper understanding of how patients think about the medical research process. Survey participants were recruited by eight of Antidote’s partners, including the American Kidney Fund, Allergy & Asthma Network, Healthline, ...

With over 2 billion daily active users, Facebook has one of the widest reaches on the internet today — especially for those trying to reach patients who may be interested in participating in clinical trials. However, because of the broad audience, there is also a lot of competition for users’ attention. This means that many advertisers must go through costly trial and error before they find the ...